CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 8.36 HKD -0.71% Market Closed
Market Cap: 4.8B HKD
Have any thoughts about
CARsgen Therapeutics Holdings Ltd?
Write Note

CARsgen Therapeutics Holdings Ltd
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CARsgen Therapeutics Holdings Ltd
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Total Current Assets
ÂĄ1.9B
CAGR 3-Years
21%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Current Assets
ÂĄ29.8B
CAGR 3-Years
-3%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Total Current Assets
ÂĄ11B
CAGR 3-Years
-6%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Current Assets
ÂĄ10.3B
CAGR 3-Years
73%
CAGR 5-Years
64%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Current Assets
ÂĄ46.8B
CAGR 3-Years
29%
CAGR 5-Years
41%
CAGR 10-Years
40%
Imeik Technology Development Co Ltd
SZSE:300896
Total Current Assets
ÂĄ4.3B
CAGR 3-Years
-1%
CAGR 5-Years
70%
CAGR 10-Years
N/A
No Stocks Found

CARsgen Therapeutics Holdings Ltd
Glance View

Market Cap
4.8B HKD
Industry
Biotechnology

CARsgen Therapeutics Holdings Ltd. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of CAR-T cell therapies. The company is headquartered in Shanghai, Shanghai and currently employs 573 full-time employees. The company went IPO on 2021-06-18. The Company’s therapies are applied in the treatment of hematological malignancies and solid tumors. The firm have developed an upgraded B cell maturation antigen (BCMA) targeted CAR-T product, CT053, which is its sole core product candidate. The firm conducts its businesses in China and the United States.

Intrinsic Value
12.81 HKD
Undervaluation 35%
Intrinsic Value
Price

See Also

What is CARsgen Therapeutics Holdings Ltd's Total Current Assets?
Total Current Assets
1.9B CNY

Based on the financial report for Dec 31, 2023, CARsgen Therapeutics Holdings Ltd's Total Current Assets amounts to 1.9B CNY.

What is CARsgen Therapeutics Holdings Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 3Y
21%

Over the last year, the Total Current Assets growth was -19%. The average annual Total Current Assets growth rates for CARsgen Therapeutics Holdings Ltd have been 21% over the past three years .

Back to Top